JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$761M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$735M |
| 3 |
Zimmer Biomet
ZBH
|
+$542M |
| 4 |
Amazon
AMZN
|
+$439M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$438M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.01B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$1.11B |
| 3 |
AABA
Altaba Inc
AABA
|
+$699M |
| 4 |
TJX Companies
TJX
|
+$682M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 22.01% |
| 2 | Financials | 14.82% |
| 3 | Technology | 12.49% |
| 4 | Healthcare | 9.61% |
| 5 | Consumer Discretionary | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
XLRN
2726
DELISTED
Acceleron Pharma
XLRN
| $4.04M | ﹤0.01% |
95,299
+3,399
| +4% | +$127K |
2017 Q3
1 quarter
|
|
|
BAS
2727
DELISTED
Basis Energy Services, Inc.
BAS
| $4.04M | ﹤0.01% |
172,145
+133,545
| +346% | +$2.78M |
2013 Q2
18 quarters
|
|
2728
Vanguard Intermediate-Term Bond ETF
BIV
$27.9B
| $4.04M | ﹤0.01% |
48,142
+3,294
| +7% | +$278K |
2015 Q1
11 quarters
|
|
|
NSH
2729
DELISTED
NuStar GP Holdings LLC
NSH
| $4.03M | ﹤0.01% |
256,636
+91,977
| +56% | +$1.53M |
2013 Q2
18 quarters
|
|
|
SAND
2730
DELISTED
Sandstorm Gold
SAND
| $4.03M | ﹤0.01% |
806,778
+243,924
| +43% | +$1.11M |
2017 Q2
2 quarters
|
|
2731
Mueller Water Products
MWA
$3.38B
| $4.01M | ﹤0.01% |
319,833
+113,605
| +55% | +$1.4M |
2013 Q2
18 quarters
|
|
|
INVX
2732
Innovex International
INVX
$1.91B
| $4M | ﹤0.01% |
83,974
-619,409
| -88% | -$27.7M |
2013 Q2
18 quarters
|
|
2733
PUT
NextEra Energy
NEE
$160B
| $4M | ﹤0.01% |
102,400
+34,400
| +51% | +$1.33M |
2017 Q1
3 quarters
|
|
|
SCG
2734
PUT
DELISTED
Scana
SCG
| $4M | ﹤0.01% |
+100,500
| New | +$4.49M |
2017 Q4
0 quarters
|
|
2735
PUT
eBay
EBAY
$47.3B
| $3.98M | ﹤0.01% |
105,400
-237,900
| -69% | -$8.83M |
2017 Q1
3 quarters
|
|
2736
Minerva Neurosciences
NERV
$157M
| $3.98M | ﹤0.01% |
82,179
+33,641
| +69% | +$1.67M |
2017 Q3
1 quarter
|
|
2737
Wabtec
WAB
$48.6B
| $3.98M | ﹤0.01% |
48,846
-490,505
| -91% | -$37.5M |
2013 Q2
18 quarters
|
|
|
DCPH
2738
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $3.97M | ﹤0.01% |
+175,181
| New | +$3.43M |
2017 Q4
0 quarters
|
|
|
TTM.RT
2739
CALL
DELISTED
TATA MOTORS LIMITED RT PUR ADR
TTM.RT
| $3.97M | ﹤0.01% |
+120,000
| New | +$3.97M |
2017 Q4
0 quarters
|
|
2740
FIVE9
FIVN
$2.57B
| $3.97M | ﹤0.01% |
159,412
+8,409
| +6% | +$207K |
2015 Q2
10 quarters
|
|
|
BFIN
2741
DELISTED
BankFinancial
BFIN
| $3.96M | ﹤0.01% |
258,236
+42,810
| +20% | +$684K |
2013 Q2
18 quarters
|
|
2742
CALL
Mohawk Industries
MHK
$8.56B
| $3.94M | ﹤0.01% |
+14,300
| New | +$3.84M |
2017 Q4
0 quarters
|
|
2743
PUT
Steris
STE
$20.3B
| $3.94M | ﹤0.01% |
+45,000
| New | +$4.01M |
2017 Q4
0 quarters
|
|
2744
CALL
Itaú Unibanco
ITUB
$94.7B
| $3.92M | ﹤0.01% |
+622,365
| New | +$3.97M |
2017 Q4
0 quarters
|
|
|
GMS
2745
DELISTED
GMS Inc
GMS
| $3.92M | ﹤0.01% |
104,123
-112,966
| -52% | -$4.03M |
2016 Q4
4 quarters
|
|
2746
Alamos Gold
AGI
$13.6B
| $3.91M | ﹤0.01% |
600,576
-251,899
| -30% | -$1.64M |
2014 Q3
13 quarters
|
|
2747
Prothena Corp
PRTA
$429M
| $3.91M | ﹤0.01% |
104,285
+5,085
| +5% | +$259K |
2014 Q4
12 quarters
|
|
2748
Triumph Financial Inc
TFIN
$1.49B
| $3.91M | ﹤0.01% |
124,018
+16,148
| +15% | +$510K |
2015 Q1
11 quarters
|
|
|
IXYS
2749
DELISTED
IXYS Corp
IXYS
| $3.9M | ﹤0.01% |
162,966
+80,579
| +98% | +$1.94M |
2013 Q2
18 quarters
|
|
2750
Gogo Inc
GOGO
$286M
| $3.89M | ﹤0.01% |
345,083
+170,042
| +97% | +$1.81M |
2016 Q3
5 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2017 Portfolio in Review
As of Q4 2017, JP Morgan Chase held 5,783 positions worth $475B, up 4.7% from $453B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q4 2017 filing shows 812 new, 2,513 increased, 1,655 reduced and 342 closed positions. Its largest new stake was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $4.01B.
By sector, the portfolio is most concentrated in Miscellaneous at 22% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M.
- JP Morgan Chase added most to Johnson & Johnson in Q4 2017, an estimated $761M increase.
- JP Morgan Chase's biggest Q4 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $4.01B.
- JP Morgan Chase fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $275M.
- JP Morgan Chase's ten largest holdings make up 18% of its $475B portfolio in Q4 2017.
- JP Morgan Chase opened 812 new positions and closed 342 in Q4 2017.
- JP Morgan Chase's portfolio value rose 4.7% quarter-over-quarter to $475B.
Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.